Covid-19: The High Authority of Health approves the use of three vaccines adapted to the Omicron variant for the new recall campaign – franceinfo

Covid-19: The High Authority of Health approves the use of three vaccines adapted to the Omicron variant for the new recall campaign – franceinfo

A few weeks after their approval by the European Medicines Agency and in connection with the resumption of the Covid-19 epidemic, the High Authority for Health (HAS) issued its opinion on the use of bivalent vaccines from Pfizer on Tuesday 20 September. and Moderna against the Omicron variant and its sublines, including the BA.5. HAS recommends the use of these vaccines as part of a recall campaign to be conducted this fall.

The institution recommends that people over the age of 60 and at risk be the first to receive a booster dose. “RECOMMENDED to extend the administration of additional revaccination (most often 2nd revaccination or 4th dose) to adults under 60 years of age who have been found to be at risk of a severe form of COVID-19, pregnant women and people living in their vicinity or in regular contact with immunocompromised or vulnerable people” , she said in a statement. Experts in healthcare and the medical-social sector should also benefit, the institution adds.

As part of this recall campaign, which HAS recommends to be established in the fall, the use of bivalent vaccines is recommended. “best”, notify the authority and “regardless of previously used vaccines”. The only exception: people under the age of 30. HAS “maintains its recommendation to use only Comirnaty vaccines”, or those developed by Pfizer.

Finally, as she recommended back in Mayinstitution “insists on its recommendation to combine the vaccination booster campaign against Covid-19 with the flu vaccination, and recalls that the injection of both vaccines on the same day is possible if it is done at two different injection sites”.

Bivalent vaccines from Pfizer and Moderna also use the famous messenger RNA technique, but have modified it to target both the original strain of the virus originating in Wuhan, China, and its Omicron variant. So there are no bivalent vaccines “not new vaccines, but vaccines adapted to circulating strains”, including Omicron sublines, specified by HAS. “LThe vaccination platform is the same, the total amount of mRNA [ARN messager NDLR] also for the dose“, adds in his press release.

If the tolerance of these vaccines “identical to monovalent vaccines”confirms the institution, emphasizes that“EThe expected clinical efficacy of these new bivalent vaccines is at least equivalent or even better than that of the original monovalent vaccines, although this likely superiority cannot currently be demonstrated in real life.”.

Either way, it calls for “continue to vaccinate at-risk persons who have not been vaccinated or who have not yet received booster doses, especially the elderly”, points out that vaccination coverage in these populations is still low, with only 32.9% of boosters given in those aged 60–79 and 46.2% in those aged 80 and over “insufficient”.

Author Image

Leave a Reply

Your email address will not be published.